Seed Grant Program

The Need for ROS1+ Research

ROS1+ cancer is relatively rare, occurring in just 1-2% of non-small cell lung cancer and other types of cancer. While oral targeted therapies are approved to treat it, the drugs don’t work for everyone, and they eventually stop working. We need more research to learn more about ROS1 biology, find better treatments, and improve quality of life and survival for all patients with this disease.

​

What We Fund

The ROS1+ Cancer Innovation Award seeks high-risk, high-reward research projects focused on ROS1+ cancer. The award provides a one-year grant of up to $75,000 to fund pre-clinical, translational, or clinical research critical to improve outcomes for ROS1+ cancer. The program is open to investigators who hold a doctorate and a faculty appointment anywhere in the world. We aim to fund three awards in 2025.

​

​